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1H NMR (400 MHz, DMSO-d6): 11.96 (s, 1 H), 7.68 (m, 1 H), 7.51-7.64 (m, 4 H), 7.30 
(dd, J1 = 12.7 Hz, J2 = 7.5 Hz, 2 H), 6.87 (d, J = 2.0 Hz, 1 H), 4.26 (m, 2 H), 3.15 (dd, J1 
= 7.9 Hz, J2 = 5.9 Hz, 1 H), 1.92 (m, 1 H), 1.62-1.79 (m, 3 H), 0.94-1.06 (m, 5 H), 0.62 
(t, J = 7.3 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6): 173.4, 159.5, 145.9, 136.4, 
135.1, 131.3, 129.7, 129.2, 129.1, 128.7, 128.6, 128.4, 126.3, 125.8, 122.1, 116.8, 45.2, 
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1H NMR (400 MHz, DMSO-d6): 12.12 (br s, 1 H), 7.48-7.61 (m, 4 H), 7.38 (d, J = 8.8 
Hz, 1 H), 7.26 (t, J = 8.8 Hz, 2 H), 6.74 (d, J = 1.5 Hz, 1 H), 5.50 (m, 1 H), 4.81 (s, 1 H), 
4.77 (d, J = 4.0 Hz, 1 H), 3.17 (m, 1 H), 2.64 (m, 2 H), 2.54 (s, 1 H); 13C NMR (150 
MHz, DMSO-d6): 160.6, 146.9, 137.2, 136.5, 135.3, 131.7, 129.5, 129.1, 129.0, 128.6, 
128.5, 128.4, 125.5, 125.3, 121.2, 117.1, 115.7, 45.8, 40.4, 33.2; HRMS (m/z): [MH]+ 
calcd. for C20H17ClNO3, 354.0897; found 354.0920 
6
1H NMR (400 MHz, DMSO-d6): 12.63 (br s, 1 H), 7.98 (d, J = 8.9 Hz, 1 H), 7.70 (dd, 
J1 = 8.9 Hz, J2 = 2.2 Hz, 1 H), 7.55-7.64 (m, 3 H), 7.30 (m, 2 H), 7.08 (d, J = 2.1 Hz, 1 
H), 3.69 (t, J = 6.9 Hz, 1 H), 2.64 (s, 3 H), 2.06 (m, 1 H), 1.56 (m, 1 H), 1.07 (m, 1 H), 
0.95 (m, 1 H), 0.65 (t, J = 7.3 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6): 174.3, 158.4, 
146.3, 144.0, 135.8, 131.6, 130.5, 130.4, 129.5, 129.4, 129.1, 128.9, 128.7, 128.6, 128.5, 
126,9, 124.5, 45.9, 31.9, 24.2, 20.7, 13.6; HRMS (m/z): [MH]+ calcd. for C21H21ClNO2, 
354.1261; found 354.1252 
7
1H NMR (400 MHz, DMSO-d6): 12.49 (br s, 1 H), 7.35 (d, J = 732 Hz, 2 H), 7.19 (d, J 
= 7.6 Hz, 2 H), 6.41 (s, 1 H), 3.74 (t, J = 6.7 Hz, 1 H), 3.27 (s, 1 H), 2.52 (s, 3 H), 2.47 (s, 
3 H), 2.40 (s, 3 H), 1.98 (m, 1 H), 1.53 (m, 1 H), 0.85-1.03  (m, 2 H), 0.62 (t, J = 7.3 Hz, 
3 H); 13C NMR (150 MHz, DMSO-d6): 174.8, 157.7, 153.2, 144.1, 139.8, 137.5, 134.4, 
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131.4, 129.2, 128.9, 128.6, 128.4, 119.0, 44.9, 32.1, 23.3, 20.9, 20.6, 16.1, 13.7; HRMS 
(m/z): [MH]+ calcd. for C21H24NO2S, 354.1522; found 354.1539  
AlphaScreen. IN/DNA binding was analyzed in a similar setting like the LEDGF/p75-IN 
Alphascreen protocol using His6-tagged integrase (1 µM final concentration) and an 
oligodeoxynucleotide mimicking the IN ELISA oligonucleotide substrate (30 nM final 
concentration). Counterscreens with JPO2 or PogZ, respectively, were essentially 
performed as described previously 27,28.  
Cell culture. HeLaP4 cells, obtained from the NIH Reagent Program, were grown in 
Dulbecco s modified Eagle s medium (DMEM) (Gibco-BRL) supplemented with 10 % 
fetal calf serum (FCS) (International Medical, Belgium), penicillin/streptomycin 
(100 µg/ml and 100 U/ml, Gibco-BRL) and geneticin (0.5 mg/ml, Gibco-BRL) (further 
referred to as DMEM-complete). Cells were incubated at 37°C and 5% CO2 in a 
humidified atmosphere. MT-4 and C8166 cells were obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH. The cells were grown 
in RPMI 1640 supplemented with 10% FCS and 20 g/ml gentamicin (RPMI-complete). 
To prepare human monocyte derived macrophages (MDM) mononuclear cells were 
purified from fresh buffy coats using Lymphoprep (Axis-Shield, USA) as described in 
the manufacturer s protocol. Subsequently human monocytes were isolated from PBMCs 
(peripheral blood mononuclear cells) through depletion of non-monocytes by MACS Cell 
Separation Columns (Milteny Biotech, Belgium). 200, 000 monocytes/well of a 24-well 
plate were seeded in RPMI (supplemented with 10 % FCS, 1/1000 Macrophage Colony 
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Stimulating Factor (MCSF) and 20 g/ml gentamicin). Differentiation to adherent 
macrophages was obtained after stimulation with MCSF for 3-5 days.  
Virus strains. The origins of HIV-1 strains, IIIB and NL4.3 51, 52, HIV-2 strains, ROD and 
EHO 53, 54, and simian immunodeficiency virus strain MAC251 55, 52 have been described 
previously. The R5 BAL and YU2 strains were obtained through the NIH AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID.  
Expression and purification of recombinant proteins. His6-tagged HIV-1 integrase, 
3xflag-tagged LEDGF/p75, MBP-JPO2 and MBP-PogZ were purified for AlphaScreen 
applications as described previously 27 ,28, 56. The core domain of HIV-1 integrase for 
crystallization and soaking was essentially purified as described by Engelman et al. 57. 
Integrase assays. The enzymatic integration reactions were carried out with minor 
modifications as described previously 58. To determine the susceptibility of the HIV-1 IN 
enzyme to different compounds, we used an enzyme-linked immunosorbent assay 
(ELISA) (adapted from 59). The overall integration assay uses an oligonucleotide 
substrate for which one oligonucleotide (5'-
ACTGCTAGAGATTTTCCACACTGACTAAAAGGGTC-3') is labeled with biotin at 
the 3' end and the other oligonucleotide (5'-
GACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGT-3') is labeled with 
digoxigenin at the 5' end. For the strand transfer assay, a precleaved oligonucleotide 
substrate (the second oligonucleotide lacks GT at the 3' end) was used. The IN enzyme 
was diluted in 750 mM NaCl, 10 mM Tris (pH 7.6), 10% glycerol, and 1 mM -
mercaptoethanol. To perform the reaction, 4 µl of diluted IN (corresponding to a 
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concentration of 1.6 µM) and 4 µl of annealed oligonucleotides (7 nM) were added in a 
final reaction volume of 40 µl containing 10 mM MgCl2, 5 mM dithiothreitol, 20 mM 
HEPES (pH 7.5), 5% polyethylene glycol, and 15% dimethyl sulfoxide. As such, the final 
concentration of IN in this assay was 160 nM. The reaction was carried out for 1 h at 
37°C. Reaction products were denatured with 30 mM NaOH and detected by ELISA on 
avidin-coated plates. For determining the effect of compounds on the 3 processing 
activity a classical cleavage assay with detection of products by denaturating gel 
electrophoresis was performed as described previously 58. Briefly, 0.2 pmol of the 
radioactive labeled oligonucleotide substrate (INT1, 32P-5 
TGTGGAAAATCTCTAGCAGT 3 ; INT2, 5 ACTGCTAGAGATTTTCCACA 3 ) and 
10 nmol IN in a final volume of 10 µl was incubated for 1 h at 37°C. The final reaction 
mixture contained 20 mM HEPES pH 7.5), 5 mM dithiothreitol (DTT), 10 mM MgCl2, 
0.5% (v/v) polyethylene glycol 8000 and 15% DMSO. IN was diluted in 750 mM NaCl, 
10 mM Tris (pH 7.6), 10% glycerol and 1 mM -mercaptoethanol. The reactions were 
stopped by the addition of formamide loading buffer (95% formamide, 0.1% xylene 
cyanol, 0.1% xylene cyanol, 0.1% bromophenol blue and 0.1% sodium dodecyl sulfate). 
Samples were loaded on a 15% denaturating polyacrylamide/urea gel. The extent of 
3 -processing or DNA strand transfer was measured based on the respective amounts of -
2 bands or strand transfer products relative to the intensity of the total radioactivity 
present in the lane. These data were determined using the OptiQuant Acquisition and 
Analysis software (Perkin Elmer Corporate, Fremont, CA). 
Drug susceptibility assays. The inhibitory effect of antiviral drugs on the HIV-induced 
CPE in MT-4 cell culture was determined by the MTT-assay 60. This assay is based on 
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the reduction of the yellow colored 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) by mitochondrial dehydrogenase of metabolically active cells to a blue 
formazan derivative, which can be measured spectrophotometrically. The 50% cell 
culture infective dose of the HIV strains was determined by titration of the virus stock 
using MT-4 cells. For the drug susceptibility assays, MT-4 cells were infected with 100 to 
300 50% cell culture infective doses (CCID50) of the HIV strains in the presence of five-
fold serial dilutions of the antiviral drugs. The concentration of the compound achieving 
50% protection against the CPE of HIV, which is defined as the 50% effective 
concentration (IC50), was determined. The concentration of the compound killing 50% of 
the MT-4 cells, which is defined as the 50% cytotoxic concentration (CC50), was 
determined as well. Infections of human PBMCs were performed with 200, 000 cells per 
well in 96-well plates in RPMI-complete. 6 and reference compounds were added at 
different concentrations and toxicity was monitored. After 6 days of infection replication 
was evaluated by p24 measurements in the supernatant. Infections of macrophages were 
performed with 1.0x105 pg p24 of the HIV-1 YU2 strain in 200µl RPMI-complete in 96-
well plates. For acute infection 6 and reference compounds were added at varying 
concentrations to the cells 30 min prior to infection. After overnight infection the medium 
was replenished. HIV-1 replication was monitored by p24 measurements in the 
supernatant at different time points after infection. For chronic infections, macrophages 
were first infected with 1.0x105 pg p24 YU2 virus in 200 µl RPMI-complete for 10 days. 
Then the supernatant was removed and was replenished with virus-free medium. 
Subsequently 6 and reference compounds at varying concentrations were added and 
replication was monitored by p24 measurements at different time points. 
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Selection of antiviral resistance. Resistance selection of HIV-1 NL4.3 against 6 was 
initiated at a low MOI (MOI = 0.01) in C8166 cells and at a drug concentration of 2 µM. 
Every 3 to 4 days the C8166 cell culture was monitored for the appearance of an HIV-
induced CPE. When CPE was observed, the cell-free culture supernatant was used to 
infect fresh, uninfected MT-4 cells in the presence of an equal or higher concentration of 
the compound. When no virus breakthrough was observed, the infected cell culture was 
subcultured in the presence of the same concentration of the compound. The compound 
concentration was gradually increased.  
PCR amplification and sequencing of the coding region of the IN and RT gene as 
well as the LTR regions. Proviral DNA extraction of C8166 cells, infected with HIV-
1(NL4.3) grown in the presence of 6, was performed using the QIAamp blood kit 
(Qiagen, Hilden, Germany). PCR amplification and sequencing of the IN-encoding 
sequence were done as described previously 61. Mutations present in more than 25% of 
the global virus population can be detected in a mixture of the mutant DNA with the 
wild-type DNA by means of population sequencing.  
Quantification of different HIV-1 DNA species during HIV infection by real-time 
PCR. HeLaP4 cells (1.0 x 106 cells per well in a 6-well plate) were incubated with HIV-1 
NL4.3 (corresponding to 1 µg of p24) in the absence or presence of the test compounds. 
Inhibitors were added to the cells 1 h prior to infection. After 2 h incubation at 37°C the 
cells were washed 3 times with phosphate buffered saline. When infection medium was 
replaced with new medium, fresh inhibitors were added. In each 6-well plate, uninfected 
HeLaP4 cells were incubated in parallel. Each time a sample was prepared for 
quantitative PCR (Q-PCR) analysis, an aliquot of uninfected cells was prepared as well. 
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DNA extractions and quantification of late reverse transcripts, two-long terminal repeat 
(2-LTR) circles, and integrants were done as described earlier 62. 
X-ray structure determination. Integrase core crystals were grown for three days at 4°C 
to a maximal size of 200 m using the hanging-drop technique with reservoir solution 
containing 10% (w/v) PEG8000, 0.1M Na cacodylate pH 6.5, 0.1M (NH4)2SO4, 5mM 
DTT (modified condition from 22. Drops were composed of 1 l of recombinant HIV-1 
integrase core domain protein at 4.4 mg ml-1 and 1 l of the reservoir. Obtained crystals 
were soaked for 12h at 4°C in the crystallization solution supplemented with 8mM 
inhibitor that had been solubilized in 0.1M DMSO. Crystals were then transferred in a 
0.1M Na cacodylate pH 6.5, 20% (w/v) PEG8000, 25% (w/v) PEG200, 0.2M (NH4)2SO4, 
5mM DTT solution and flash-frozen in liquid nitrogen. 
Diffraction data were collected at 100K using 1.0Å radiation at the X06DA beamline of 
the Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland, using a Mar225 
CCD detector, indexed with iMosflm 46 and scaled with Scala 46 . The PDB entry 1HYV 
(without tetraphenylarsenium compound) was used as a starting point for the structural 
refinement in Refmac 5.546. Although the integrase core domain was crystallized 
essentially as described by Molteni et al. 22, we observed small differences in the 
integrase residues that could be located in the electron density maps. Our structure 
includes residues 55 to 145, 153 to 188 and 193 to 209 whether the Molteni et al. 
structure includes residues 57 to 140, 148 to 189 and 193 to 210. The rmsd between both 
structures is 0.315Å. The inhibitor structure was built into the difference (Fo-Fc) map 
using Coot 46. The final structure has excellent geometry, with 98.5% of residues in 
preferred regions of the Ramachandran plot with no outliers. 
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Supplementary Results  
 
Supplementary Figure 1: As part of a virtual screening work flow, the pharmacophore 
search was carried out according to a funnel by which 25 compounds were finally 
selected from a commercial database. Validation of these compounds using Alphascreen 
resulted in 4 initial hits of which the most interesting was used for further research. 
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Supplementary Figure 2: Synthesis of 6. 
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Supplementary Figure 3: Co-crystal structure of 3 bound in the IBD binding pocket of 
the integrase catalytic core domain. The two chains of the integrase dimer are shown in 
pale green and pale yellow. Difference electron density (Fobserved -Fcalculated,2 level) for 
the compound is shown. Hydrogen bonds made by the carboxyl moiety of 3 to the protein 
backbone near residues Glu170, His171 and Thr173 are shown as green dashed lines. 
This image was rendered with PyMol in stereoscopic mode.  
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Supplementary Table 1. Inhibition of integrase activities.  
HIV-1 overall (IC50)a
 
strand transfer (IC50)a 3 processing (IC50)a
6 54.88±24.43 19.5±7.5 >250 
raltegravir 0.08±0.012 0.067±0.001 n.d.b
HIV-2 
6 >250 >250 n.d. 
HIV-1 A128T 
6 >250 >250 n.d. 
aConcentration required to inhibit the in vitro catalytic reactions of integrase by 50%. The 
average and standard deviations of at least 2 independent experiments are shown. bnot 
determined. 
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Supplementary Table 2. Antiviral activity spectrum of 2-(quinolin-3-yl)acetic acid 
derivatives  
Virus class Virus strain 6a
 
raltegravirb AZTb efavirenzb
HIV-1 IIIB 2.73±0.86 5.8±0.2 26.5±17.2 1.4±0.2 
HXB2D 2.13±0.08 4.0±1.15 8.33±0.98 1.25±0.15 
NL4.3 11.52±2.3 3.6±0.1 16.8±8.3 1.45±0.2 
ZKNL4.3 7.29±2.73 3.5±1.9 7.8±1.5 1.5±0.2 
HIV-2 EHO >125 4.5±0.1 1±0.1 >2 
ROD >125 5.3±1.8 17.3±11.2 >2 
SIV MAC251 >125 5.3±2.1 0.65±0.3 >2 
aEffective concentration required to reduce HIV-1induced cytopathic effect by 50% in 
MT-4 cells in micromolar concentration [µM]. bEffective concentration required to 
reduce HIV-1 induced cytopathic effect by 50% in MT-4 cells in nanomolar 
concentration [nM]. The average and standard deviations of at least 3 independent 
experiments are shown. 
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Supplementary Table 3. Antiviral activity in primary cells.  
Cell type Virus strain 6a
 
Raltegravira AZTa
PBMC IIIBb 3.45±0.69 0.0052±0.0035 0.011±0.0023 
BALc 12.7±2.4 0.0086±0.00092 0.0342±0.024 
Macrophages YU2c 14.77±1.61 0.14±0.1 0.1±0.02 
aEffective concentration required to reduce HIV-1 replication by 50% in PBMC or 
macrophages in micromolar concentration [µM] as determined by p24 measurement. 
bHIV-1 strain using the CXCR4 chemokine coreceptor for cellular entry. cHIV-1 strain 
using the CCR5 chemokine coreceptor for cellular entry. The average and standard 
deviations of 3 independent experiments are shown. 
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EC50c(µM) CC50d(µM)       SIe
7 0.58±0.30 5.88±0.10 0.76±0.08 72.16±5.15 95 
        
              7 
aConcentration required to inhibit in vitro protein-protein interaction by 50%. 
bConcentration required to inhibit the in vitro overall catalytic activity of IN by 50%. 
cEffective concentration required to reduce HIV-1 induced cytopathic effect by 50% in 
MT-4 cells. dCytotoxic concentration reducing MT-4 cell viability by 50%. eSelectivity 
index: ratio CC50/EC50. The average and standard deviations of at least 3 independent 
experiments are shown.  
NS O
OH
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Supplementary Table 5. Crystallographic data collection and refinement statistics  
Compound 3 soak (3LPT) Compound 6 soak (3LPU) 
Data collection   
Space group P3121 P3121 
Cell dimensions
   
    a, b, c (Å) 72.00, 72.00, 65.49 72.05, 72.05, 66.35 
( )  90, 90, 120 90, 90, 120 
Resolution (Å) 31 2.00 (2.11 2.00*) 33 1.90 (2.00 1.90*) 
R sym 0.086 (0.277) 0.051 (0.237)  
<I / I> 18.2 (4.1) 17.9 (5.8) 
Completeness (%) 99.6 (97.7) 99.9 (100)  
Redundancy 4.7 (4.8) 4.8 (4.9)     
Refinement   
Resolution (Å) 2.00 1.95 
No. reflections 13555 14135 
Rwork / Rfree 0.231/0.272 0.203/221 
No. atoms   
    Protein 1147 1145 
    Ligand/ion 82 41 
    Water 92 125 
B-factors   
    Protein 30.3 28.5 
    Ligand/ion 64.6 48.0 
    Water 44.3 44.6 
R.m.s. deviations   
    Bond lengths (Å) 0.01 0.01 
    Bond angles ( ) 1.4 1.3 
*Highest-resolution shell is shown in parentheses   
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